{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:14:20Z","timestamp":1783379660163,"version":"3.54.6"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128407","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:56:38Z","timestamp":1772643398000},"page":"128407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Benefit-risk assessment of HPV vaccination programs in Australia, the United States, and Japan"],"prefix":"10.1016","volume":"78","author":[{"given":"Miwa","family":"Satake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiho","family":"Sawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Scuffham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsura","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2026.128407_bb0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","article-title":"Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis","volume":"88","author":"Clifford","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2026.128407_bb0010","series-title":"Global strategy to accelerate the elimination of cervical cancer as a public health problem","author":"WHO","year":"2020"},{"key":"10.1016\/j.vaccine.2026.128407_bb0015","unstructured":"WHO Newsroom. Global immunization coverage 2024. 15 July 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/immunization-coverage (Accessed on 21 Nov. 2025)."},{"key":"10.1016\/j.vaccine.2026.128407_bb0020","unstructured":"National Cancer for Immunisation Research and Surveillance Australia. Annual Immunisation Coverage Report 2024. https:\/\/ncirs.org.au\/sites\/default\/files\/2025-10\/Annual%20Immunisation%20Coverage%20Report%202024.pdf (Accessed on 25 Nov. 2025)."},{"key":"10.1016\/j.vaccine.2026.128407_bb0025","doi-asserted-by":"crossref","unstructured":"Pingali C, Yankey D, Elam-Evans LD, Trahan A, Markowitz LE, DeSisto CL, Hughes M, Valier MR, Stokley S, Singleton JA. Vaccination coverage among adolescents aged 13\u201317 years \u2014National immunization survey-teen, United States, 2024. CDC Morbid Mortal Weekly Rep (MMWR) 74, 30, 2025. https:\/\/www.cdc.gov\/mmwr\/volumes\/74\/wr\/pdfs\/mm7430a1-H.pdf [Accessed on 25 Nov. 2025].","DOI":"10.15585\/mmwr.mm7430a1"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128407_bb0030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.35772\/ghm.2023.01010","article-title":"Underlying background of the current trend of increasing HPV vaccination coverage in Japan","volume":"5","author":"Namba","year":"2023","journal-title":"Glob Health Med"},{"key":"10.1016\/j.vaccine.2026.128407_bb0035","unstructured":"Ueda Y. Cumulative HPV vaccination rate by the end of fiscal year 2024. Materials from the 107th Adverse Reaction Review Subcommittee of the Immunization and Vaccine Subcommittee of the Health and Science Council, and the 3rd FY2025 Pharmaceutical Affairs Council Drug Safety Subcommittee Safety Investigation Committee (Japanese only). https:\/\/www.mhlw.go.jp\/content\/11120000\/001522679.pdf (Accessed on 25 Nov. 2025)."},{"key":"10.1016\/j.vaccine.2026.128407_bb0040","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2307\/1914185","article-title":"Prospect theory: an analysis of decision under risk","volume":"47","author":"Kahneman","year":"1979","journal-title":"Econometrica"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128407_bb0045","doi-asserted-by":"crossref","first-page":"140","DOI":"10.36469\/jheor.2022.34721","article-title":"Assessing the health and economic outcomes of a 9-valent HPV vaccination program in the United Kingdom","volume":"9","author":"Owusu-Edusei","year":"2022","journal-title":"J Health Econ Outcomes Res"},{"issue":"19","key":"10.1016\/j.vaccine.2026.128407_bb0050","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.vaccine.2014.01.081","article-title":"Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012","volume":"32","author":"Larson","year":"2014","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128407_bb0055","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1248\/yakushi.22-00142","article-title":"Establishment of mono-scaled benefit\/risk analysis of HPV vaccine","volume":"142","author":"Tsukamoto","year":"2022","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.vaccine.2026.128407_bb0060","unstructured":"Health and Welfare Science Council (Vaccination and Vaccine Subcommittee, Adverse Reaction Review Subcommittee) minutes No.1-No.107. https:\/\/www.mhlw.go.jp\/stf\/shingi\/shingi-kousei_284075old2.html (Accessed on 25 Nov. 2025)."},{"key":"10.1016\/j.vaccine.2026.128407_bb0065","unstructured":"Australian Government Department of Health, Disability and Aging. National Cervical Screening Program monitoring report 2023 https:\/\/www.aihw.gov.au\/reports\/cancer-screening\/ncsp-monitoring-2023\/summary (Accessed on 2 Dec. 2025)."},{"key":"10.1016\/j.vaccine.2026.128407_bb0070","unstructured":"Cancer Council Australia. HPV vaccination uptake. https:\/\/ncci.canceraustralia.gov.au\/prevention\/hpv-vaccination-uptake\/hpv-vaccination-uptake (Accessed on 5 Aug. 2024)."},{"key":"10.1016\/j.vaccine.2026.128407_bb0075","unstructured":"Cancer Council Australia. Cervical cancer in Australia statistics. https:\/\/www.canceraustralia.gov.au\/cancer-types\/cervical-cancer\/cervical-cancer-australia-statistics (Accessed on 2 Dec. 2025)."},{"key":"10.1016\/j.vaccine.2026.128407_bb0080","unstructured":"Database of Adverse Event Notifications (DAEN). https:\/\/www.tga.gov.au\/safety\/adverse-events\/database-adverse-event-notifications-daen (Accessed on 5 Aug. 2024)."},{"key":"10.1016\/j.vaccine.2026.128407_bb0085","unstructured":"Centers for Disease Control and Prevention (CDC). https:\/\/www.cdc.gov\/cervical-cancer\/ (Accessed on 25 Nov. 2025)."},{"key":"10.1016\/j.vaccine.2026.128407_bb0090","unstructured":"Vaccine Adverse Event Reporting System (VAERS). https:\/\/vaers.hhs.gov\/ (Accessed on 5 Aug. 2024)."},{"key":"10.1016\/j.vaccine.2026.128407_bb0095","unstructured":"U.S. Food and Drug Administration. Vaccines Licensed for Use in the United States. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/vaccines-licensed-use-united-states (Accessed on 25 Nov. 2025)."},{"key":"10.1016\/j.vaccine.2026.128407_bb0100","author":"Institute for Health Metrics and Evaluation"},{"issue":"2 Suppl","key":"10.1016\/j.vaccine.2026.128407_bb0105","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1177\/0272989X98018002S09","article-title":"Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis","volume":"18","author":"Stinnett","year":"1998","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vaccine.2026.128407_bb0110","series-title":"Methods for The Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2002"},{"issue":"10197","key":"10.1016\/j.vaccine.2026.128407_bb0115","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128407_bb0120","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-7-38","article-title":"Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease","volume":"7","author":"Serrano","year":"2012","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.vaccine.2026.128407_bb0125","author":"FDA"},{"key":"10.1016\/j.vaccine.2026.128407_bb0130","author":"FDA"},{"key":"10.1016\/j.vaccine.2026.128407_bb0135","author":"Australian Institute of Health and Welfare"},{"key":"10.1016\/j.vaccine.2026.128407_bb0140","author":"National Cancer Institute"},{"key":"10.1016\/j.vaccine.2026.128407_bb0145","author":"Health and Welfare Science Council (Vaccination and Vaccine Subcommittee, Adverse Reaction Review Subcommittee)"},{"key":"10.1016\/j.vaccine.2026.128407_bb0150","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2147\/CLEP.S135318","article-title":"Psychiatric conditions and general practitioner attendance prior to HPV vaccination and the risk of referral to a specialized hospital setting because of suspected adverse events following HPV vaccination: a register-based, matched case-control study","volume":"9","author":"L\u00fctzen","year":"2017","journal-title":"Clin Epidemiol"},{"issue":"2\u20133","key":"10.1016\/j.vaccine.2026.128407_bb0155","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12026-014-8575-3","article-title":"A sudden onset of a pseudo-neurological syndrome after HPV-16\/18 AS04-adjuvated vaccine: might it be an autoimmune\/inflammatory syndrome induced by adjuvants (ASIA) presenting as a somatoform disorder?","volume":"60","author":"Poddighe","year":"2014","journal-title":"Immunol Res"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128407_bb0160","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12026-016-8820-z","article-title":"Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature","volume":"65","author":"Palmieri","year":"2017","journal-title":"Immunol Res"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128407_bb0165","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/pds.3636","article-title":"Balancing benefit and risk of medicines: a systematic review and classification of available methodologies","volume":"23","author":"Mt-Isa","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"36","key":"10.1016\/j.vaccine.2026.128407_bb0170","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128407_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.128111","article-title":"Determinants of human papillomavirus vaccination decision-making in Japan: a scoping review exploring contextual, social, and adolescent-specific influences","volume":"72","author":"Tomoi","year":"2026","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128407_bb0180","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/cid\/ciw647","article-title":"Trends of media coverage on human papillomavirus vaccination in Japanese newspapers","volume":"63","author":"Tsuda","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128407_bb0185","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/aje\/kwz253","article-title":"Effectiveness of 1, 2, and 3 doses of human papillomavirus vaccine against high-grade cervical lesions positive for human papillomavirus 16 or 18","volume":"189","author":"Johnson Jones","year":"2020","journal-title":"Am J Epidemiol"},{"issue":"10224","key":"10.1016\/j.vaccine.2026.128407_bb0190","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","article-title":"Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Brisson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128407_bb0195","unstructured":"Director-General of the Health Bureau of the Ministry of Health, Labour and Welfare. Maintaining and securing consultation and support systems and medical care systems when promoting routine vaccinations against human papillomavirus infection. Health and Welfare Notification 1228 No. 1. December 28, 2021 (Accessed on 25 Nov. 2025)."},{"key":"10.1016\/j.vaccine.2026.128407_bb0200","author":"The Japan Society of Gynecologic Oncology"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128407_bb0205","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"issue":"30","key":"10.1016\/j.vaccine.2026.128407_bb0210","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1016\/j.vaccine.2021.05.051","article-title":"School-based HPV vaccination positively impacts parents\u2019 attitudes toward adolescent vaccination","volume":"39","author":"Davies","year":"2021","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.vaccine.2026.128407_bb0215","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.vaccine.2016.03.087","article-title":"Can the vaccine adverse event reporting system be used to increase vaccine acceptance and trust?","volume":"34","author":"Scherer","year":"2016","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600215X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600215X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:26:44Z","timestamp":1783376804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2600215X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":43,"alternative-id":["S0264410X2600215X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128407","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefit-risk assessment of HPV vaccination programs in Australia, the United States, and Japan","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128407"}}